AstraZeneca PLC (AZN)vsSionna Therapeutics, Inc. Common Stock (SION)
AZN
AstraZeneca PLC
$158.75
-0.16%
HEALTHCARE · Cap: $263.09B
SION
Sionna Therapeutics, Inc. Common Stock
$6.25
+22.55%
HEALTHCARE · Cap: $2.13B
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
SION
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+19.3%
Fair Value
$196.68
Current Price
$158.75
$37.93 discount
Intrinsic value data unavailable for SION.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : SION
The strongest argument for SION centers on Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : SION
The primary concerns for SION are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while SION is a value play — different risk/reward profiles.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (60/100 vs 25/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sionna Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Sionna Therapeutics, Inc. is an innovative biotechnology company focused on developing advanced therapies for neurodegenerative disorders, notably Alzheimer's and Parkinson's diseases linked to protein misfolding. The company boasts a robust pipeline supported by proprietary technologies aimed at addressing substantial unmet medical needs within this urgent therapeutic space. Through strategic partnerships and a strong commitment to research and development, Sionna is well-positioned to become a leader in the biopharmaceutical sector, dedicated to enhancing patient outcomes and overall quality of life with its groundbreaking neurological treatments.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?